191 related articles for article (PubMed ID: 31525692)
1. A long acting nanoformulated lamivudine ProTide.
Smith N; Bade AN; Soni D; Gautam N; Alnouti Y; Herskovitz J; Ibrahim IM; Wojtkiewicz MS; Dyavar Shetty BL; McMillan J; Gendelman HE; Edagwa B
Biomaterials; 2019 Dec; 223():119476. PubMed ID: 31525692
[TBL] [Abstract][Full Text] [Related]
2. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice.
Wang W; Smith N; Makarov E; Sun Y; Gebhart CL; Ganesan M; Osna NA; Gendelman HE; Edagwa BJ; Poluektova LY
Nanomedicine; 2020 Aug; 28():102185. PubMed ID: 32217146
[TBL] [Abstract][Full Text] [Related]
3. Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine.
Guo D; Zhou T; Araínga M; Palandri D; Gautam N; Bronich T; Alnouti Y; McMillan J; Edagwa B; Gendelman HE
J Acquir Immune Defic Syndr; 2017 Mar; 74(3):e75-e83. PubMed ID: 27559685
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of a long acting nanoformulated emtricitabine ProTide.
Soni D; Bade AN; Gautam N; Herskovitz J; Ibrahim IM; Smith N; Wojtkiewicz MS; Dyavar Shetty BL; Alnouti Y; McMillan J; Gendelman HE; Edagwa BJ
Biomaterials; 2019 Nov; 222():119441. PubMed ID: 31472458
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a long-acting nanoformulated abacavir prodrug.
Singh D; McMillan J; Hilaire J; Gautam N; Palandri D; Alnouti Y; Gendelman HE; Edagwa B
Nanomedicine (Lond); 2016 Aug; 11(15):1913-27. PubMed ID: 27456759
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Characterization of Long-Acting Darunavir Prodrugs.
Banoub MG; Bade AN; Lin Z; Cobb D; Gautam N; Dyavar Shetty BL; Wojtkiewicz M; Alnouti Y; McMillan J; Gendelman HE; Edagwa B
Mol Pharm; 2020 Jan; 17(1):155-166. PubMed ID: 31742407
[TBL] [Abstract][Full Text] [Related]
7. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
[TBL] [Abstract][Full Text] [Related]
8. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
McConnachie LA; Kinman LM; Koehn J; Kraft JC; Lane S; Lee W; Collier AC; Ho RJY
J Pharm Sci; 2018 Jul; 107(7):1787-1790. PubMed ID: 29548975
[TBL] [Abstract][Full Text] [Related]
9. Long-acting slow effective release antiretroviral therapy.
Edagwa B; McMillan J; Sillman B; Gendelman HE
Expert Opin Drug Deliv; 2017 Nov; 14(11):1281-1291. PubMed ID: 28128004
[TBL] [Abstract][Full Text] [Related]
10. Creation of a long-acting rilpivirine prodrug nanoformulation.
Hilaire JR; Bade AN; Sillman B; Gautam N; Herskovitz J; Dyavar Shetty BL; Wojtkiewicz MS; Szlachetka A; Lamberty BG; Sravanam S; Fox HS; Alnouti Y; Dash PK; McMillan JM; Edagwa BJ; Gendelman HE
J Control Release; 2019 Oct; 311-312():201-211. PubMed ID: 31491432
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation.
Ibrahim IM; Bade AN; Lin Z; Soni D; Wojtkiewicz M; Dyavar Shetty BL; Gautam N; McMillan JM; Alnouti Y; Edagwa BJ; Gendelman HE
Int J Nanomedicine; 2019; 14():6231-6247. PubMed ID: 31496683
[TBL] [Abstract][Full Text] [Related]
12. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir.
Gautam N; McMillan JM; Kumar D; Bade AN; Pan Q; Kulkarni TA; Li W; Sillman B; Smith NA; Shetty BLD; Szlachetka A; Edagwa BJ; Gendelman HE; Alnouti Y
Nat Commun; 2021 Jun; 12(1):3453. PubMed ID: 34103484
[TBL] [Abstract][Full Text] [Related]
13. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues.
Kevadiya BD; Ottemann B; Mukadam IZ; Castellanos L; Sikora K; Hilaire JR; Machhi J; Herskovitz J; Soni D; Hasan M; Zhang W; Anandakumar S; Garrison J; McMillan J; Edagwa B; Mosley RL; Vachet RW; Gendelman HE
Theranostics; 2020; 10(2):630-656. PubMed ID: 31903142
[TBL] [Abstract][Full Text] [Related]
14. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
[TBL] [Abstract][Full Text] [Related]
15. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.
Tetteh RA; Nartey ET; Lartey M; Mantel-Teeuwisse AK; Leufkens HG; Nortey PA; Dodoo AN
BMC Public Health; 2015 Jun; 15():573. PubMed ID: 26092496
[TBL] [Abstract][Full Text] [Related]
16. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
18. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
Fox Z; Dragsted UB; Gerstoft J; Phillips AN; Kjaer J; Mathiesen L; Youle M; Katlama C; Hill A; Bruun JN; Clumeck N; Dellamonica P; Lundgren JD;
Antivir Ther; 2006; 11(6):761-70. PubMed ID: 17310820
[TBL] [Abstract][Full Text] [Related]
20. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]